A new PDUFA target date is April 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for STS101 (dihydroergotamine [DHE] nasal ...

In this study, the first to compare the pharmacokinetics, tolerability and safety of nasally and orally administered zolmitriptan in healthy Japanese subjects, zolmitriptan nasal spray 2.5 and 5mg ...

Migraine treatment may be classified as prophylactic ... Abortive drugs can be given by self-injection, by oral route or by nasal spray. Although oral preparations have the slowest onset, they ...

If that doesn’t work? “The safest way to pop your ears is to perform a maneuver called a modified Valsalva manoeuvre, which ...

With a selection of products ranging from pet supplies to home fitness and furnishings, Walmart and Amazon offer a huge ...

Exenatide is a GLP-1 agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with ...

STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma's proprietary nasal delivery device.